Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.44 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6932339 | 0.84 | GABRA5 (0.55) | — | |
| SCHEMBL6929982 | 0.84 | GABRA5 (0.55) | — | |
| SCHEMBL1461188 | 0.83 | CHRNB2 (0.52) | CXCR2 | |
| SCHEMBL2159138 | 0.83 | CHRNB2 (0.52) | CXCR2 | |
| SCHEMBL2159038 | 0.83 | CHRNB2 (0.52) | CXCR2 | |
| SCHEMBL2158694 | 0.82 | GABRA5 (0.51) | KDM4EALDH1A1HPGDCYP1A2CYP3A4 | |
| SCHEMBL2158698 | 0.82 | GABRA5 (0.51) | KDM4EALDH1A1HPGDCYP1A2CYP3A4 | |
| SCHEMBL7453238 | 0.78 | HDAC1 (0.51) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL9989282 | 0.78 | HDAC1 (0.51) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL6930884 | 0.78 | GRM5 (0.68) | CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-07-28 | — | — | US | disclosed |
| WO-2011035324-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | VANDERBILT UNIVERSITY (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183980-A1 | O-BENZYL NICOTINAMIDE ANALOGS AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS | GRM5, GRIK5, GRM1 | KDM4E 1200/4885ALDH1A1 4082/4885HPGD 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.